OBJECTIVE: A challenge in the management of breast cancer is development of brain metastases (BM) with limited survival. In primary breast cancer, ER/PR/HER2 are important prognostic markers and are important for making effective treatment decisions. Changes in immunohistochemical markers of metastases are with unclear clinical significance, and mechanisms of resistance to endocrine therapy are an additional challenge. The aim of this retrospective study is to detect changes in immunohistochemical markers of primary and BM and to recognize if receptor change has prognostic impact. METHODS: Twenty-four consecutive primary breast cancer patients who developed BM and got surgical resection of BM were enrolled. Matched pair analyses of primary and BM were done with evaluation by immunostaining (ER/PR/HER2). RESULTS: A small tumor size, ductal histology and HER2+ tumors were associated with BM. Loss of ER/PR receptor positivity was observed in BM compared to primary (ER: 50.0 %/22.7 %; p = 0.004; PR: 45.8 %/9.1 %; p = n.s), respectively, and almost no change in HER2 status (>80 %; p = 0.012). Patients with ER-/PR-negative or HER2-positive primary had shorter time to recurrence than ER-/PR-positive and HER2-negative patients. Receptor change has negative prognostic impact. CONCLUSION: With the observed loss of receptor positivity, therapeutic options are diminished. Identification of patients with a high risk for BM is warranted to evaluate preventive strategies.
OBJECTIVE: A challenge in the management of breast cancer is development of brain metastases (BM) with limited survival. In primary breast cancer, ER/PR/HER2 are important prognostic markers and are important for making effective treatment decisions. Changes in immunohistochemical markers of metastases are with unclear clinical significance, and mechanisms of resistance to endocrine therapy are an additional challenge. The aim of this retrospective study is to detect changes in immunohistochemical markers of primary and BM and to recognize if receptor change has prognostic impact. METHODS: Twenty-four consecutive primary breast cancerpatients who developed BM and got surgical resection of BM were enrolled. Matched pair analyses of primary and BM were done with evaluation by immunostaining (ER/PR/HER2). RESULTS: A small tumor size, ductal histology and HER2+ tumors were associated with BM. Loss of ER/PR receptor positivity was observed in BM compared to primary (ER: 50.0 %/22.7 %; p = 0.004; PR: 45.8 %/9.1 %; p = n.s), respectively, and almost no change in HER2 status (>80 %; p = 0.012). Patients with ER-/PR-negative or HER2-positive primary had shorter time to recurrence than ER-/PR-positive and HER2-negative patients. Receptor change has negative prognostic impact. CONCLUSION: With the observed loss of receptor positivity, therapeutic options are diminished. Identification of patients with a high risk for BM is warranted to evaluate preventive strategies.
Authors: Nicola Normanno; Massimo Di Maio; Ermelinda De Maio; Antonella De Luca; Andrea de Matteis; Antonio Giordano; Francesco Perrone Journal: Endocr Relat Cancer Date: 2005-12 Impact factor: 5.678
Authors: Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart Journal: Lancet Date: 2007-01-06 Impact factor: 79.321
Authors: F Heitz; J Rochon; P Harter; H-J Lueck; A Fisseler-Eckhoff; J Barinoff; A Traut; F Lorenz-Salehi; A du Bois Journal: Ann Oncol Date: 2010-11-08 Impact factor: 32.976
Authors: B C Pestalozzi; D Zahrieh; K N Price; S B Holmberg; J Lindtner; J Collins; D Crivellari; M F Fey; E Murray; O Pagani; E Simoncini; M Castiglione-Gertsch; R D Gelber; A S Coates; A Goldhirsch Journal: Ann Oncol Date: 2006-04-07 Impact factor: 32.976
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Elyse E Lower; D Randolph Drosick; Robbin Blau; Lawrence Brennan; William Danneman; Douglas K Hawley Journal: Clin Breast Cancer Date: 2003-06 Impact factor: 3.225
Authors: Susanne Taucher; Margaretha Rudas; Robert M Mader; Michael Gnant; Peter Dubsky; Thomas Bachleitner; Sebastian Roka; Florian Fitzal; Daniela Kandioler; Emanuel Sporn; Josef Friedl; Martina Mittlböck; Raimund Jakesz Journal: Cancer Date: 2003-12-15 Impact factor: 6.860
Authors: S Dawood; K Broglio; F J Esteva; W Yang; S-W Kau; R Islam; C Albarracin; T K Yu; M Green; G N Hortobagyi; A M Gonzalez-Angulo Journal: Ann Oncol Date: 2009-01-15 Impact factor: 32.976
Authors: Paul W Sperduto; Shane Mesko; Jing Li; Daniel Cagney; Ayal Aizer; Nancy U Lin; Eric Nesbit; Tim J Kruser; Jason Chan; Steve Braunstein; Jessica Lee; John P Kirkpatrick; Will Breen; Paul D Brown; Diana Shi; Helen A Shih; Hany Soliman; Arjun Sahgal; Ryan Shanley; William Sperduto; Emil Lou; Ashlyn Everett; Drexell Hunter Boggs; Laura Masucci; David Roberge; Jill Remick; Kristin Plichta; John M Buatti; Supriya Jain; Laurie E Gaspar; Cheng-Chia Wu; Tony J C Wang; John Bryant; Michael Chuong; James Yu; Veronica Chiang; Toshimichi Nakano; Hidefumi Aoyama; Minesh P Mehta Journal: Neuro Oncol Date: 2020-09-29 Impact factor: 12.300
Authors: C Bachmann; S Schmidt; A Staebler; T Fehm; F Fend; J Schittenhelm; D Wallwiener; E Grischke Journal: Med Oncol Date: 2014-11-30 Impact factor: 3.064
Authors: R Costa; B A Carneiro; D A Wainwright; C A Santa-Maria; P Kumthekar; Y K Chae; W J Gradishar; M Cristofanilli; F J Giles Journal: Ann Oncol Date: 2017-01-01 Impact factor: 51.769
Authors: Sherise D Ferguson; Siyuan Zheng; Joanne Xiu; Shouhao Zhou; Mustafa Khasraw; Priscilla K Brastianos; Santosh Kesari; Jethro Hu; Jeremy Rudnick; Michael E Salacz; David Piccioni; Suyun Huang; Michael A Davies; Isabella C Glitza; John V Heymach; Jianjun Zhang; Nuhad K Ibrahim; John F DeGroot; Joseph McCarty; Barbara J O'Brien; Raymond Sawaya; Roeland G W Verhaak; Sandeep K Reddy; Waldemar Priebe; Zoran Gatalica; David Spetzler; Amy B Heimberger Journal: Int J Cancer Date: 2018-10-09 Impact factor: 7.396